The Christine Mayr Lab: Publications

Visit PubMed for a full listing of Christine Mayr’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Manuscripts submitted

Ma W, Mayr C. A subcellular compartment defined by TIS granules and the ER enables 3′UTR-mediated protein-protein interactions. in revision

Lee SH, Mayr C. Diversification of BIRC3 protein functions through 3′UTR-encoded instructions. in revision

Regulation of protein localization and protein functions by 3’UTRs

Mayr C. Protein complexes assemble while they are being made. Nature (2018)

Mayr C. What are 3’UTRs doing? Cold Spring Harbor Perspectives in Biology (2018).

Mayr C. Regulation by 3′-Untranslated Regions. Annu Rev Genet 51:171-194 (2017). PMID: 28853924 PDF

Mayr C. Evolution and Biological Roles of Alternative 3’UTRs. Trends Cell Biol 26, 227-237 (2016). PMID:26597575 PDF 

Berkovits BD, Mayr C.  Alternative 3’UTRs act as scaffolds to regulate membrane protein localization. Nature 522, 363-367 (2015). Epub 2015 Apr 20. PMID:25896326 PDF

  • Highlighted in Nature Reviews Molecular Cell Biology PDF

Alternative polyadenylation

Lee SH*, Singh I*, Tisdale S, Abdel-Wahab O, Leslie CS, Mayr C. Widespread intronic polyadenylation inactivates tumor suppressor genes in leukemia. Nature, in press.

Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS.  Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat commun 9: 1716 (2018). PMCID: PMC5928244 PDF 

Lianoglou S, Garg V, Yang JL, Leslie CS, Mayr C. Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. GenesDev 27, 2380-2396 (2013). PMID:24145798 PDF

  • Selected by Science Signaling as one of the Breakthroughs of 2013 PDF
  • Recommended by the Faculty of 1000

Mayr C, Bartel DP. Widespread shortening of 3’UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684 (2009). PMID:19703394 PDF

  • Highlighted in Nature PDF
  • Highlighted in Nature Reviews Genetics PDF
  • Designated as “Exceptional” by the Faculty of 1000

Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 456,470-476 (2008). PMID:18978772

  • Designated as “Exceptional” by the Faculty of 1000

Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579 (2007). Epub 2007 Feb 22. PMID:17322030 PDF

  • Highlighted in Nature Reviews Cancer PDF
  • Highlighted in Journal of the American Chemical Society PDF 
  • Highlighted in Science PDF

Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104, 7080-7085 (2007). Epub 2007 Apr 16. PMID:17438277

Immunotherapy and prognostic factors in CLL

Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel L, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114, 3255-3264 (2009). Epub 2009 Aug 19.

Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, Zeidler R, Moosmann A. Conditional immortalization of human B cells by CD40 ligation. PloS ONE 3, e1464 (2008). PMID:18213373

Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol  35, 920-930 (2007). PMID:17533046

Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Exp Hematol 34, 860-869 (2006). PMID:16797413

Kofler DM, Mayr C, Wendtner CM. Current status of immunotherapy in B cell malignancies. Curr Drug Targets 7, 1371-1374 (2006). PMID:17073599

Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner CM. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 34, 44-53 (2006). PMID:16413390

Mayr C, Speicher MR, Kofler DM, Buhmann R, Busch R, Strehl J, Hallek M, Wendtner CM. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107, 742-751 (2006). Epub 2005 Sep 22. PMID:16179374

Mayr C, Kofler DM, Büning H, Bund D, Hallek M, Wendtner C-M. Transduction of CLL cells by CD40 ligand (CD40L) enhances an antigen specific immune recognition by autologous T cells. Blood 106, 3223-3226 (2005). Epub 2005 Jul 12. PMID:16014560

Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner C-M. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105, 1566-1573 (2005). Epub 2004 Oct 7. PMID:15471955

Kofler DM, Büning H, Mayr C, Bund D, Baumert J, Hallek M, Wendtner CM. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70 positive B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11, 1416-1424 (2004). PMID:15269708

Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma 45, 897-904 (2004). PMID:15291346

Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, Ziske C, Schmidt-Wolf IG. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma is superior to conventional chemotherapy in selected patients: a meta-analysis. Haematologica 88, 1304-1315 (2003). PMID:14607760

Mayr C, Radzom S, Dreyling M. Neurotoxicity under chemotherapy with high doses of cytarabine. Arzneimitteltherapie 19, 296-298 (2001).

Hildebrandt M, Rose M, Mayr C, Arck P, Schüler C, Reutter W, Salama A, Klapp BF. Dipeptidyl peptidase IV (DPP IV, CD 26) in patients with mental eating disorders. Adv Exp Med Biol 477, 197-204 (2000). PMID:10849747

Hildebrandt M, Rose M, Mayr C, Schüler C, Reutter W, Salama A, Klapp BF. Alterations in expression and in serum activity of dipeptidyl peptidase IV (DPP IV, CD 26) in patients with hyporectic eating disorders. Scand J Immunol 50, 536-541 (1999). PMID:10564557